Anzeige
Mehr »
Donnerstag, 15.01.2026 - Börsentäglich über 12.000 News
Strategischer Schachzug: Germanium Mining sichert sich massives Flächenpotenzial im Kampf um die High-Tech-Vorherrschaft
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
456 Leser
Artikel bewerten:
(2)

Elsevier and Medical Education Technologies, Inc. Collaborate to Offer Simulation Technology for Health Science Curriculums

ST. LOUIS, Missouri, May 23, 2011 /PRNewswire/ --

- Partnership Fully Integrates Nursing Education Content and Solutions With Human Patient Simulators

Elsevier, (http://www.elsevier.com/wps/find/homepage.cws_home) the leading global publisher of scientific, technical, and medical information products and services, announced today a partnership agreement with Medical Education Technologies, Inc. (http://www.meti.com/index.html ) (METI), a leading manufacturer of medical simulation and health care learning technologies. The companies will collaborate to release a turn-key health care education product that combines Elsevier's nursing education content with METI's human patient simulators.

"Nursing programs around the country are looking for more effective ways to prepare the future health care workforce for success in the realities of clinical practice," said Tom Wilhelm, Vice President, e-solutions, Elsevier Nursing and Health Professions. "This new solution will provide nursing students with hands-on learning when clinical space is at a premium, and offer the training and experience they need to handle new and emerging best practices and technologies. For educators, this product provides a solution that enables them to deliver simulated clinical experiences without having to manually change each setting in the patient simulator."

Elsevier and METI will combine METI's human patient simulators integrated with Müse(R), a medical trainer's simulator operating software, with Elsevier's current suite of nursing simulation products, including Sim Chart, a new simulated EHR and charting system, and Simulation Learning System (SLS), an online toolkit that helps instructors and facilitators effectively standardize and incorporate medium to high fidelity simulation into their nursing curriculum.

"Elsevier and METI's new offering is a seamless solution that will make it much easier for us to integrate simulation activities into our nursing program and provide more comprehensive training for future nurses," said Kim Leighton, Dean of Educational Technology, BryanLGH College of Health Sciences. "The new product will allow us to spend more time preparing our students for real-life clinical situations they will face in the workplace, and less time preparing our simulation activities."

The combined solution is available to nursing education programs and schools through Elsevier or METI. Customers who have already purchased a METI human patient simulator can integrate the Elsevier content for the complete solution. Elsevier will also continue to offer its education content without METI simulators, and METI simulators are available without Elsevier content. More information can be found at http://www.elsevieradvantage.com/simulations/ or http://www.meti.com/products_lm_pnci.htm.

"This partnership comes at a crucial time because of the current shortage of clinical sites for nursing and health professional education," said Michael Bernstein, President and CEO of METI. "In addition, incentives in the government's recent health care legislation are driving increased adoption of simulation technology. Elsevier is highly regarded in nursing education and shares our vision and commitment to provide technology that supports the direction health care is going and the advancement of real-world training that improves patient safety and ultimately, saves lives."

About METI

Based in Sarasota, Florida, METI has been a leader in interactive human patient simulation since 1996. The entire family of METI simulators, including baby, pediatric and adults, are designed to mimic human medical scenarios including trauma, heart attack, drug overdose and effects of bioterrorism. Today, more than 7,000 METI simulators are in use worldwide by defense organizations, medical schools, nursing schools, hospitals and other entities involved in healthcare education. METI is privately owned by Lou Oberndorf and Baird Capital Partners (BCP) of Chicago.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.meti.com/index.html) and Cell, (http://www.cell.com/) and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, (http://www.sciencedirect.com/) SciVerse Scopus, (http://www.scopus.com/home.url) Reaxys, (https://www.reaxys.com/info/) MD Consult (http://www.mdconsult.com/php/249791713-138/homepage) and Nursing Consult, ( http://confidenceconnected.com/login/consult?env=PROD&URI=/nursing/index) which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com/) and MEDai's Pinpoint Review, (http://www.medai.com/) which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com/wps/find/homepage.cws_home) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, ( http://www.reedelsevier.com/Pages/Home.aspx) a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    
    Media Contact

    Tom Reller
    Vice President, Global Corporate Relations
    +1-215-239-3508
    T.Reller@Elsevier.com

© 2011 PR Newswire
Renditeturbo 2026 - 5 Aktien mit Potenzial
2025 neigt sich dem Ende zu, ohne klassische Jahresendrallye, aber mit einem DAX, der viele Kritiker Lügen gestraft hat. Über 21 Prozent Kursplus seit Jahresbeginn, stärker als der US-Markt. Wer hätte das noch vor Monaten erwartet?

Genau solche Entwicklungen machen den Reiz der Börse aus. Denn auch 2026 dürfte wieder alles anders kommen als gedacht. Während viele Analysten weiter steigende Kurse erwarten, rückt eine zentrale Frage in den Fokus: Wo entstehen im kommenden Jahr echte Überraschungen, und wie kann man davon profitieren?

Unser aktueller Spezialreport beleuchtet fünf Entwicklungen, mit denen kaum jemand rechnet, die aber enormes Renditepotenzial bergen. Vom Comeback der Ölwerte über unterschätzte Plattform-Aktien bis hin zur möglichen Wachablösung im KI-Sektor: Wer 2026 überdurchschnittlich abschneiden will, muss antizyklisch denken und frühzeitig Position beziehen.

Im kostenlosen Report stellen wir 5 Aktien vor, die 2026 im Zentrum solcher Wendepunkte stehen könnten. Solide bewertet, gut positioniert und mit überraschend starkem Momentum.

Jetzt kostenlos herunterladen! Bevor andere erkennen, wo die Chancen wirklich liegen!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.